Harvard Bioscience Joins with BroadOak Capital
I'm PortAI, I can summarize articles.
Harvard Bioscience announced a $40 million credit facility agreement with BroadOak Capital Partners, consisting of three term loans to be funded by December 17, 2025. The funds will retire existing debt and strengthen the company's balance sheet. Term Loan C is convertible into shares at $1.00 per share. BroadOak received warrants for two million shares at $0.50 each and can nominate a board member. HBIO shares rose 5.6% to 74 cents.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Baystreet The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments